Segall Bryant & Hamill LLC Has $14.68 Million Stake in Insulet Co. (NASDAQ:PODD)

Segall Bryant & Hamill LLC raised its position in shares of Insulet Co. (NASDAQ:PODD) by 33.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 63,052 shares of the medical instruments supplier’s stock after acquiring an additional 15,683 shares during the quarter. Segall Bryant & Hamill LLC owned about 0.09% of Insulet worth $14,675,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Blue Trust Inc. increased its holdings in Insulet by 84.1% in the third quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 58 shares in the last quarter. Venturi Wealth Management LLC increased its stake in shares of Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 133 shares in the last quarter. International Assets Investment Management LLC acquired a new position in shares of Insulet during the 2nd quarter valued at $32,000. UMB Bank n.a. boosted its stake in Insulet by 81.0% during the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after acquiring an additional 81 shares in the last quarter. Finally, CVA Family Office LLC grew its holdings in Insulet by 138.1% in the second quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock worth $50,000 after purchasing an additional 145 shares during the period.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $266.58 on Thursday. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $279.40. The company’s 50-day moving average is $240.09 and its 200 day moving average is $209.62. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The company has a market capitalization of $18.70 billion, a P/E ratio of 45.65, a price-to-earnings-growth ratio of 3.98 and a beta of 1.22.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on PODD shares. UBS Group upped their price objective on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a report on Friday, August 9th. Citigroup upped their price target on Insulet from $250.00 to $275.00 and gave the stock a “buy” rating in a research note on Tuesday, October 1st. Piper Sandler raised their price objective on Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th. Barclays boosted their price objective on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Finally, Sanford C. Bernstein assumed coverage on Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $253.27.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.